The Technical Analyst
Select Language :

Obseva SA [OBSV]

Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Obseva SA is listed at the NASDAQ Exchange

0.00% $2.24

Last updated: 28 Nov 2021 @ 18:02 pm


FUNDAMENTALS
MarketCap: 174.66 mill
EPS: -0.822
P/E: 0.000
Earnings Date: Nov 04, 2021
SharesOutstanding: 77.97 mill
Avg Daily Volume: 0.808 mill
RATING 2021-11-26
B+
Neutral
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
1/202/203/204/201/212/21
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0.000 | sector: PE 371.73
PE RATIO: COMPANY / INDUSTRY
0.00x
Company: PE 0.000 | industry: PE 479.09
DISCOUNTED CASH FLOW VALUE
$2.92
(30.19%) $0.676
Date: 2021-11-28

Forecast: 14:40 - $2.23

Live Trading Signals (every 1 min)

Forecast 1: 13:10 - $2.23
Forecast 2: 14:00 - $2.23
Forecast 3: 14:40 - $2.23
SCORE
-0.68
Hold
Score Algorithm Version: 0.9M
Last version updated: Thurs 28th Oct 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.24 (0.00% )
Volume 0.384 mill
Avg. Vol. 0.808 mill
% of Avg. Vol 47.51 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Obseva SA

Last 12 Months

Last 12 months chart data with high, low, open and close for Obseva SA

RSI

Intraday RSI14 chart for Obseva SA
The Live Chart for Obseva SA
Profile picture for
            Obseva SA

OBSV

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Last 10 Buy Signals
Date Signal @
XRPUSDNov 28 - 12:590.914
BTCUSDNov 28 - 12:3054 098
XRPUSDNov 28 - 12:260.920
XRPUSDNov 28 - 12:230.921
XRPUSDNov 28 - 12:190.922
BTCUSDNov 28 - 12:1654 220
XRPUSDNov 28 - 12:130.923
BTCUSDNov 28 - 12:1054 267
BTCUSDNov 28 - 12:0454 208
BTCUSDNov 28 - 12:0054 239

Stock Peers

Company Price Change
OBSV2.240.00%
ASLN1.5302.68%
CDMOP25.060.04%
CRBP0.884-3.06%
CTIC2.485.98%
KIN9.250.11%
MNOV3.22-9.80%
ORPH3.30-2.94%
SMTI28.65-1.21%
TCDA7.40-3.77%
VTVT1.340-2.19%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.